Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1137-1140

  Katodritou, E ^a   Gastari, V ^a   Verrou, E ^a   Hadjiaggelidou, C ^a   Varthaliti, M ^a   Georgiadou, S ^a   Laschos, K ^a   Xirou, P ^a   Yiannaki, E ^a   Constantinou, N ^a   Markala, D ^a   Zervas, K ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Biological features; EMP relapse; Myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE COURSE; EXTRAMEDULLARY PLASMACYTOMA RELAPSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOPHENOTYPING; LABORATORY TEST; MALE; MOLECULAR GENETICS; MORPHOLOGY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMACYTOMA; PRIORITY JOURNAL; RARE DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 67349154980     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.01.036     Document Type: Article

References (13)

1. Alegre A., Granda A., Martínez-Chamorro C., Díaz-Mediavilla J., Martínez R., García-Laraña J., et al. Spanish Registry of Transplants in Multiple Myelomas; Spanish Group of Hemopoietic Transplant (GETH); PETHEMA. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica 87 (2002) 609-614
2. Balleari E., Ghio R., Falcone A., and Musto P. Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. Leukemia Lymphoma 45 (2004) 735-738
3. Sahara N., Takeshita A., Shigeno K., Fujisawa S., Takeshita K., Naito K., et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 117 (2002) 882-885
4. Dawson M.A., Patil S., and Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 92 (2007) 143-144
5. Rosinol L., Cibeira M.T., Blade J., Esteve J., Aymerich M., Rozman M., et al. Extramedullary myeloma escapes the effect of thalidomide. Haematological 89 (2004) 832-836
6. Epstein J., Xiao H.Q., and He X.Y. Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med 322 (1990) 664-668
7. Sahara N., Ohnishi K., Ono T., Sugimoto Y., Kobayashi M., Takeshita K., et al. Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma. Eur J Haematol 77 July (1) (2006) 14-18
8. Lemoli R.M., Fortuna A., Grande A., Gamberi B., Bonsi L., Fogli M., et al. Expression and functional role of c-kit ligand (SCF) in human multiple myeloma. Cells Br J Haematol 88 (1994) 760-769
9. Guikema J.E., Hovenga S., Vellenga E., Conradie J.J., Abdulahad W.H., Bekkema R., et al. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol 121 (2003) 36-43
10. Guikema J.E., Vellenga E., Abdulahad W.H., Hovenga S., and Bos N.A. CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases. Br J Haematol 124 (2004) 299-308
11. Katodritou E., Kartsios C., Gastari V., Verrou E., Mihou D., Banti A., et al. Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported case. Leukemia Res 32 (2008) 339-341
12. Katodritou E., Verrou E., Gastari V., Hadjiaggelidou C., Terpos E., and Zervas K. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leukemia Res 32 (2008) 1153-1156
13. Pirrotta M.T., Gozzetti A., Cerase A., Bucalossi A., Bocchia M., Defina M., et al. Unusual discordant responses in two multiple myeloma patients during bortezomib treatment. Onkologie 31 (2008) 45-47